Home › NDC Lookup › Ingredients › Nystatin › 72578-0089-01
Nystatin 100000 U/g Ointment, 15 g — NDC 72578-0089-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Nystatin 100000 U/g Ointment, 15 g — NDC 72578-089-01 (Billing 72578-0089-01)

by Viona Pharmaceuticals Inc · 15 g in 1 TUBE

This is a package of 15 g of Nystatin 100000 U/g Ointment from Viona Pharmaceuticals Inc, marketed since Jun 2020 and currently FDA-listed; retail pharmacies pay about $0.2331 per g (NADAC).

NDC 72578-0089-01
🏷️ FDA NDC (as labeled) 72578-089-01 billing pads the product segment with a zero
This package
Contains15 g Cost per g$0.2331 NADAC Per package$3.50 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.5204/unit · Part D plans $0.4011/unit — full pricing hub ↓
Product page 72578-0089-04 Also comes in: 30 g 72578-089-04
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 72578-089-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
72578 labeler · 089 product · 01 package
Package marketed since
Jun 24, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
15 g per package
Barcode (UPC)
0372578089016
Medicaid fills, this package
25,199 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Nystatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 23, 2026 — Subpotent Drug: Low out of specification assay results performed during long-term stability testing. (Padagis US LLC) · FDA recall D-0677-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 72578-089-01
Product NDC 72578-089
11-digit billing NDC 72578008901
NCPDP billing unit GM — per gram (weight)
RxCUI 884308
UNII BDF1O1C72E
UPC 0372578089016
Application # ANDA207767
SPL Set ID e135a7d2-adba-48a2-b3e1-07b778cce9b0
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-06-24
Route TOPICAL
Dosage form OINTMENT
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080004215
GPI class Nystatin
GCN Seq No 007283
GCN 30150
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYSTATIN 100,000 UNIT/GM OINT
FDB brand name Nystatin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007283
  • GCN: 30150
  • GPI-14 (Medi-Span): 90150080004215
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 884308
Why two NDCs? The FDA registers this code as 72578-089-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72578-0089-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYSTATIN 100,000 UNIT/GM OINT Ingredient Nystatin
📖 What it is MedlinePlus · NLM

Topical nystatin is used to treat fungal infections of the skin. Nystatin is in a class of antifungal medications called polyenes. It works by stopping the growth of fungi that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.233 $3.50 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.5204 $7.81 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.4011 $6.02 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.465 $0.229
▼ Down 50% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
72578-0089-01 You're viewing this 15 g in 1 TUBE $0.2331 / g $3.50 2020-06-24 — Active
72578-0089-04 72578-089-04 Main listing 30 g in 1 TUBE $0.2375 / g $7.13 2020-06-24 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-g cost of the 2 priced pack sizes ($0.2331 NADAC).

This pack accounts for about 23% of this product's recent Medicaid fills; most go to the 30 g pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 15 g — 15 g in 1 tube.
How does this package differ from NDC 72578-0089-04?
Both are Nystatin 100000 U/g Ointment — the drug itself is identical. This page's package is the 15 g one, while NDC 72578-0089-04 is the 30 g package. Per-g NADAC also differs: $0.2331 here vs $0.2375 for the 30 g pack.
What NDC number is used to bill for this package of Nystatin 100000 U/g Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystatin 100000 U/g 13668-0595-01 Torrent 15 g $0.198 AT Availability likely save 15%
Nystatin 100000 [USP'U]/g 00472-0166-15 Actavis 1 tube $0.233 AT Availability likely —
Nystatin 100000 [USP'U]/g 00713-0686-15 Cosette 1 tube $0.233 AT Availability likely —
Nystatin 100000 U/g 13668-0534-01 Torrent 15 g $0.233 AT Availability likely —
Nystatin 100000 1/g 33342-0481-15 Macleods 1 tube $0.233 AT Availability likely —
Nystatin 100000 U/gthis 72578-0089-01 Viona 15 g $0.233 AT Availability likely —
Nystatin 100000 [USP'U]/g 45802-0048-11 Padagis 1 tube $0.238 AT Availability likely +2%
Nystatin 100000 [USP'U]/g 69315-0307-15 Leading 1 tube $0.334 AT FDA listed +44%
Nystatin 100000 U/g 50090-5845-00 A-S 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 63187-0464-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 63629-2515-01 Bryant 30 g — AT FDA listed —
Nystatin 100000 U/g 63629-2516-01 Bryant 15 g — AT FDA listed —
Nystatin 100000 U/g 70771-1357-01 Zydus 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 71205-0437-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 72162-2007-02 Bryant 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 72162-2333-02 Bryant 1 tube — AT FDA listed —
Nystatin 100000 U/g 82804-0045-15 Proficient 15 g — AT FDA listed —
Nystatin 100000 U/g 68788-8631-01 Preferred 15 g — AT FDA listed —
Nystatin 100000 U/g 72162-2576-02 Bryant 15 g — AT FDA listed —
Nystatin 100000 U/g 50090-7303-00 A-S 15 g — AT FDA listed —
Nystatin 100000 U/g 67296-1519-01 RedPharm 15 g — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Jun 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Yellow
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerViona Pharmaceuticals Inc
Application holderZYDUS LIFESCIENCES LTD
FDA applicationANDA207767 (ANDA)
Labeler code72578
First marketedJun 2020
Product typeHuman Prescription Drug
Portfolio94 products on file

More NDCs from Viona Pharmaceuticals Inc labeler code 72578

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 37 words ▾

INDICATIONS AND USAGE Nystatin Ointment is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nystatin Ointment is not indicated for systemic, oral, intravaginal or ophthalmic use.

⏱️ Dosage and Administration 26 words ▾

DOSAGE AND ADMINISTRATION NYSTATIN Ointment Adults and Pediatric Patients (Neonates and Older): Apply liberally to affected areas twice daily or as indicated until healing is complete.

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS Nystatin Ointment is contraindicated in patients with a history of hypersensitivity to any of their components.

🤒 Adverse Reactions 41 words ▾

ADVERSE REACTIONS The frequency of adverse events reported in patients using Nystatin Ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General . )

🧒 Pediatric Use 21 words ▾

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. See DOSAGE AND ADMINISTRATION

🧬 Clinical Pharmacology 155 words ▾

CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C.parapsilosis, C.tropicalis, C.guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes . Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.

On repeated subculturing with increasing concentrations of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida ( C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides ) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.

This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

📦 How Supplied / Storage and Handling 36 words ▾

HOW SUPPLIED Nystatin ointment (100,000 USP Nystatin Units per gram) is a yellow colored ointment is supplied in 15g and 30g tubes. NDC 72578-089-01 in tube of 15 gm NDC 72578-089-04 in tube of 30 gm

📦 Storage and Handling 31 words ▾

STORAGE NYSTATIN Ointment: Store at room temperature. Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.

📋 Description 46 words ▾

DESCRIPTION Nystatin is a polyene antifungal antibiotic drug obtained from Streptomyces nursei. Structural formula: Nystatin Ointment is for dermatologic use. Nystatin Ointment USP, for topical use only, contains 100,000 USP Nystatin Units per gram, in a white petrolatum and light mineral oil base. Nystatin Ointment, USP

💬 Information for Patients ~1 min read ▾

INFORMATION FOR PATIENTS Patients using these medications should receive the following information and instructions: The patient should be instructed to use these medications as directed (including the replacement of missed doses). These medications are not for any disorder other than that for which they are prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms of irritation develop, the patient should be advised to notify the physician promptly Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

Pregnancy: Teratogenic Effects Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.

Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. See DOSAGE AND ADMINISTRATION

⚠️ Precautions 64 words ▾

PRECAUTIONS General Nystatin Ointment should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

🍼 Nursing Mothers 25 words ▾

Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

🧬 Pharmacokinetics 11 words ▾

Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.

📄 Package Label / Principal Display Panel 19 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 72578-089-01 Nystatin Ointment USP, 15 g Rx only tube 15 g 15 g carton label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
25.2K
Units reimbursed last 4 qtrs
551.8K
Gross reimbursed last 4 qtrs
$287.2K
Avg / prescription
$11.40
Avg / unit
$0.5204
Latest quarter Q1 2026
4.7KRx
Medicaid pays / g
$0.5204
gross reimbursed
vs
NADAC / g
$0.2331
acquisition cost
=
Spread
+$0.2873
+123% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
26% FFS 74% MCO
Fee-for-service · 6,462 Rx Managed care · 18,737 Rx
State Medicaid map
Alaska: no data reported AK Maine: 3,450 units · 247 per 100k residents ME Washington: 3,675 units · 47.0 per 100k residents WA Idaho: 983 units · 50.1 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 3,810 units · 66.4 per 100k residents MN Wisconsin: 2,859 units · 48.4 per 100k residents WI Michigan: 26,350 units · 263 per 100k residents MI New York: 64,156 units · 328 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 2,145 units · 50.7 per 100k residents OR Nevada: 1,545 units · 48.4 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 3,030 units · 94.5 per 100k residents IA Illinois: 7,830 units · 62.4 per 100k residents IL Indiana: 19,993 units · 291 per 100k residents IN Ohio: 37,016 units · 314 per 100k residents OH Pennsylvania: 35,355 units · 273 per 100k residents PA New Jersey: 54,345 units · 585 per 100k residents NJ Massachusetts: 2,957 units · 42.2 per 100k residents MA California: 6,985 units · 17.9 per 100k residents CA Utah: 255 units · 7.5 per 100k residents UT Colorado: 6,960 units · 118 per 100k residents CO Nebraska: 1,768 units · 89.4 per 100k residents NE Missouri: 9,005 units · 145 per 100k residents MO Kentucky: 19,609 units · 433 per 100k residents KY West Virginia: 5,310 units · 300 per 100k residents WV Virginia: 8,933 units · 102 per 100k residents VA Maryland: 20,760 units · 336 per 100k residents MD Connecticut: 1,695 units · 46.9 per 100k residents CT Rhode Island: no data reported RI Arizona: 5,535 units · 74.5 per 100k residents AZ New Mexico: 1,650 units · 78.1 per 100k residents NM Kansas: 2,830 units · 96.3 per 100k residents KS Arkansas: 8,745 units · 285 per 100k residents AR Tennessee: 11,464 units · 161 per 100k residents TN North Carolina: 8,662 units · 79.9 per 100k residents NC South Carolina: 6,105 units · 114 per 100k residents SC Delaware: 1,485 units · 144 per 100k residents DE Oklahoma: 2,595 units · 64.0 per 100k residents OK Louisiana: 12,135 units · 265 per 100k residents LA Mississippi: 6,556 units · 223 per 100k residents MS Alabama: 2,835 units · 55.5 per 100k residents AL Georgia: 14,500 units · 131 per 100k residents GA D.C.: 285 units · 42.0 per 100k residents DC Hawaii: no data reported HI Texas: 107,086 units · 351 per 100k residents TX Florida: 3,910 units · 17.3 per 100k residents FL
Units reimbursed · per 100k residents
7.5585
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 585 /100k
2 Kentucky 433 /100k
3 Texas 351 /100k
4 Maryland 336 /100k
5 New York 328 /100k
6 Ohio 314 /100k
7 West Virginia 300 /100k
8 Indiana 291 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 g72578-0089-04 84,496 Rx · $1,290,532
15 g this page72578-0089-01 25,199 Rx · $287,158
Drug total (last 4 qtrs): 109,695 Rx · 3,499,641 units · $1,577,690 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nystatin — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nystatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.29M
Claims incl. refills
853.7K
Beneficiaries
614.3K
Spend / beneficiary
$26.52
Spend / claim
$19.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 72578-0088-01 · Viona 72578-0090-01 · Viona →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.